Openbookopenbook
Equity
Kissei Pharmaceutical Co. Ltd(KSPHF)
USD --+0.00%
Reward60Moderate
Risk28Low
📊75%Data
3.0% dividend yield · Revenue growing 16% YoY
KSPHF
+0.0 · +0.00%
USD · PINK
Kissei Pharmaceutical Co. Ltd | Healthcare
Defensive Anchor
Market Cap:1.19Bn
ℹ️
Reward Rating
60
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
28
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on KSPHF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Kissei Pharmaceutical Co. Ltd?

researches, develops, manufactures, and sells pharmaceutical products primarily in Japan.

KSPHF · Verdict

Solid reward · low risk

KSPHF stands out on balance sheet and valuation, but watch the cash flow signal.

Based on 88% data coverage

KSPHF · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet99/100

    Interest covered 744.3×

  • Valuation75/100

    Above average

  • Volatility75/100

    Above average

Watchouts 1

  • Cash flow45/100

    2% free-cash-flow margin

Model-based scoring. For information only — not financial advice.

What is Kissei Pharmaceutical Co. Ltd?

researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.19B, and a P/E ratio of 12.2x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.19B
P/E Ratio12.2036
Dividend Yield2.98%
52 Week High31.9
52 Week Low22.2774
Last AnnualMarch
IPO DateN/A
IncorporatedUSA
Shares Outstanding41M
No. of Employees1,778
IndustryDrug Manufacturers - Specialty & Generic
ExchangePINK
Beta-0.259
CurrencyUSD · Reports in JPY
Websitewww.kissei.co.jp
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.